Lynparza (olaparib)

pCPA File Number: 21166
Negotiation Status:
Concluded with an LOI
Indication(s):
Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CADTH Project Number:
10174
pCPA Engagement Letter Issued:
Negotiation Process Concluded: